Instructions for Amaryl (Glimepiride) pills
English product name
Amaryl®
Release form
tab 1 mg: 30, 60, 90 or 120 pcs
tab 2 mg: 30, 60, 90 or 120 pcs
tab 3 mg: 30, 60, 90 or 120 pcs
tab 4 mg: 30, 60, 90 or 120 pcs
Description Amaryl:
Blue coloured tablets, oblong, flat, with a separation risk on both sides, engraved with "NMo" and stylized with "h" on both sides.
1 tab.
glymepiride 4 mg
Auxiliary substances: lactose monohydrate 135.85 mg, sodium carboxymethyl starch (type A) - 8 mg, povidon 25000 - 1 mg, microcrystalline cellulose - 20 mg, magnesium stearate - 1 mg, indigocarmine (E132) - 0.15 mg.
15 pcs - blister packs (2) - cardboard packs.
15 pcs - blister packs (4) - cardboard packs.
15 pcs - blister packs (6) - cardboard packs.
15 pcs - blister packs (8) - cardboard packs.
ATC codes Amaryl
A10BB12 Glimepiride
Clinical-pharmacological groups / Group affiliation
Oral hypoglycemic preparation
Active substance
glymepiride
Pharmacotherapy group Amaryl:
Hypoglycemic agent for oral administration of sulfonyl urea group of III generation
Storage Conditions
List B. The drug should be stored in a place inaccessible to children at a temperature not higher than 30 ° C.
Best before date
The shelf life is three years.
Testimony Amaryl:
- type 2 diabetes (as a monotherapy or as part of a combination therapy with metformin or insulin).
Method of use, course and dosage:
As a rule, the dose of Amaryl® is determined by the target blood glucose concentration. The drug should be used at a minimum dose sufficient to achieve the necessary metabolic control.
During treatment with Amaryl® it is necessary to regularly determine the level of glucose in the blood. Regular monitoring of glycosylated hemoglobin levels is also recommended.
A disorder in taking the drug, such as missing a regular dose, should not be remedied by taking the drug at a higher dose afterwards.
The doctor should instruct the patient in advance about the actions to be taken in case of mistakes in taking Amaryl® (in particular, when skipping a regular dose or skipping a meal), or in situations where it is not possible to take the drug.
Application for kidney disorders
It is contraindicated to use in cases of severe disorders of kidney function (including for patients who are on haemodialysis);
Use in liver disorders
It is contraindicated application in case of severe liver dysfunctions.
Terms of Sale
The drug is prescription.
Use in children
It is contraindicated in childhood.
- Nosology (ICD codes)
- E11
- Type 2 diabetes
Pharmacological effect Amaryl:
The oral hypoglycemic preparation is a third generation sulfonyl urea derivative.
Glymepiride reduces blood glucose concentration, mainly by stimulating insulin release from pancreatic β cells. Its effect is mainly related to improving the ability of pancreatic β cells to respond to physiological glucose stimulation. Compared to glybenclamide, glymepiride in low doses causes the release of less insulin when the blood glucose concentration is approximately the same. This fact indicates that glymepiride has extrapancreatic hypoglycemic effects (increased sensitivity of tissues to insulin and insulin effect).